Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
July 2019
-
Media Release
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +… -
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from… -
Media Release
Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention
After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11… -
Story People and Culture
Flexibility at Novartis: Janneke van der Kamp
Van der Kamp explains how leading by example has encouraged others to adopt flexible working models.
-
Featured News
Global Health & Corporate Responsibility
Novartis transforms its Global Health & Corporate Responsibility organization. -
Media Release
Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine
Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women… -
Media Release
Novartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)
Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in secondary… -
Key Release
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both… -
Media Release
Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies
Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures … -
Media Release
Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed
Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
June 2019
-
Media Release
Novartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasis
New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1]… -
Story People and Culture
Flexibility at Novartis: Christine Sturchler and Aileen Wrynn
Sturchler and Wrynn explain why their job-sharing experience was one of the most successful and energizing periods of their careers.